More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026
Go back to More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026| BARNES GROUP, Inc. (NYSE: B) | Delayed: 42.50 -1.18 (2.7%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $43.68 | 52 Week High | $44.27 | |||
| Open | $42.47 | 52 Week Low | $30.07 | |||
| Day High | $42.83 | P/E | 32.44 | |||
| Day Low | $41.88 | EPS | $1.31 | |||
| Volume | 5,319,565 | |||||
| BIOAMBER, Inc. (NASDAQ: BIOA) | Delayed: 8.44 -0.05 (0.59%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $8.49 | 52 Week High | $8.73 | |||
| Open | $8.52 | 52 Week Low | $2.86 | |||
| Day High | $8.64 | P/E | N/A | |||
| Day Low | $8.39 | EPS | $-3.82 | |||
| Volume | 328,429 | |||||
